Qiu Yuan, Takaya Hiroki, Maeda Kay, Messika-Zeitoun David, Ruel Marc, Mesana Thierry, Chan Vincent
Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, ON K1Y 4W7, Canada.
J Cardiovasc Dev Dis. 2023 Feb 23;10(3):95. doi: 10.3390/jcdd10030095.
Degenerative mitral valve (MV) disease is the most common cause of organic mitral regurgitation (MR) in developed countries. Surgical mitral valve repair is the gold standard treatment for primary MR. Surgical mitral valve repair is associated with excellent outcomes in terms of survival and freedom from recurrent MR. As well, innovations in surgical repair techniques, including thoracoscopically and robotically assisted approaches, further reduce morbidity. Emerging catheter-based therapies may also provide advantages in select patient groups. Although the outcomes following surgical mitral valve repair are well described in the literature, longitudinal follow-up is heterogenous. Indeed, longitudinal follow-up and long-term data are vital to better advise treatment and counsel patients.
退行性二尖瓣疾病是发达国家器质性二尖瓣反流（MR）最常见的病因。外科二尖瓣修复术是原发性MR的金标准治疗方法。外科二尖瓣修复术在生存率和无复发性MR方面具有出色的疗效。此外，外科修复技术的创新，包括胸腔镜和机器人辅助方法，进一步降低了发病率。新兴的基于导管的治疗方法在特定患者群体中也可能具有优势。虽然外科二尖瓣修复术后的疗效在文献中有充分描述，但纵向随访并不一致。事实上，纵向随访和长期数据对于更好地指导治疗和为患者提供咨询至关重要。
